儿童心脏骤停后治疗性低温:两项随机对照试验的汇总分析
该汇总分析合并了两项设计相同的儿童心脏骤停后目标温度管理随机对照试验的个体患者数据,共纳入624例在恢复循环后6小时内仍昏迷的儿童,目标温度分别为33.0℃(低温组)或36.8℃(常温组)。主要终点为骤停后12个月生存且VABS-II评分≥70,在骤停前VABS-II≥70的517例中,低温组28%(75/271)与常温组26%(63/246)无显著差异(RR 1.08,95%CI 0.81–1.42,P=0.61)。1年生存率(44% vs 38%,RR 1.15,95%CI 0.95–1.38,P=0.15)及VABS-II评分变化、不良事件均无显著差异。结论认为低温相较常温未在1年生存伴良好功能结局方面带来显著获益。
要点
- 在骤停前VABS-II≥70的517例患儿中,低温组与常温组主要终点(12个月生存且VABS-II≥70)无显著差异:28%(75/271)vs 26%(63/246),RR 1.08(95%CI 0.81–1.42)。
- 1年生存率低温组44%(138/317)与常温组38%(113/297)无显著差异,RR 1.15(95%CI 0.95–1.38,P=0.15)。
- 602例可评估患儿中,VABS-II评分从基线至12个月的变化两组无显著差异(P=0.20)。
- 输血制品、感染、严重心律失常不良事件及28天死亡率两组无显著差异。
- 目标温度为33.0℃(低温)或36.8℃(常温),随机化在恢复循环后6小时内完成。
适用人群与场景
- 年龄≥48小时至18岁的儿童,复苏后仍处于昏迷状态,在恢复循环后6小时内随机化。
- 来自美国、加拿大和英国的41个儿科重症监护病房,包括院外和院内心脏骤停病例。
诊断标准与关键阈值
- 主要终点评估人群为骤停前VABS-II评分≥70的患儿(VABS-II评分范围20–160,分数越高功能越好,人群均值100,SD 15)。
- 主要终点定义为骤停后12个月生存且VABS-II评分≥70。
处置流程与药物剂量
- 低温组目标温度33.0℃,常温组目标温度36.8℃。
研究设计与关键结果
- 研究类型:两项设计相同的随机对照试验的个体患者数据汇总分析,共624例随机化,来自41个儿科重症监护病房。
- 主要终点:在517例骤停前VABS-II≥70的患儿中,低温组28%(75/271)vs 常温组26%(63/246),RR 1.08(95%CI 0.81–1.42,P=0.61),无显著差异。
- 关键次要终点:602例可评估患儿中VABS-II评分从基线至12个月的变化两组无显著差异(P=0.20);VABS-II下降≤15分或较基线改善的比例低温组22% vs 常温组21%。
- 1年生存率:低温组44%(138/317)vs 常温组38%(113/297),RR 1.15(95%CI 0.95–1.38,P=0.15),无显著差异。
- 不良事件:输血制品使用、感染、严重心律失常不良事件及28天死亡率两组无显著差异。
证据类型、等级与局限
- 证据类型:两项随机对照试验的汇总分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于儿童心脏骤停后昏迷患者,低温(目标33.0℃)相较常温(目标36.8℃)未在1年生存伴良好神经行为结局方面显示显著获益;作者结论为低温未带来显著获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Separate trials to evaluate therapeutic hypothermia after paediatric cardiac arrest for out-of-hospital and in-hospital settings reported no statistically significant differences in survival with favourable neurobehavioral outcome or safety compared to therapeutic normothermia. However, larger sample sizes might detect smaller clinical effects. Our aim was to pool data from identically conducted trials to approximately double the sample size of the individual trials yielding greater statistical power to compare outcomes.
METHODS: Combine individual patient data from two clinical trials set in forty-one paediatric intensive care units in USA, Canada and UK. Children aged at least 48 h up to 18 years old, who remained comatose after resuscitation, were randomized within 6 h of return of circulation to hypothermia or normothermia (target 33.0 °C or 36.8 °C). The primary outcome, survival 12 months post-arrest with Vineland Adaptive Behaviour Scales, Second Edition (VABS-II) score at least 70 (scored from 20 to 160, higher scores reflecting better function, population mean = 100, SD = 15), was evaluated among patients with pre-arrest scores ≥70.
RESULTS: 624 patients were randomized. Among 517 with pre-arrest VABS-II scores ≥70, the primary outcome did not significantly differ between hypothermia and normothermia groups (28% [75/271] and 26% [63/246], respectively; relative risk, 1.08; 95% confidence interval [CI], 0.81 to 1.42; p = 0.61). Among 602 evaluable patients, the change in VABS-II score from baseline to 12 months did not differ significantly between groups (p = 0.20), nor did, proportion of cases with declines no more than 15 points or improvement from baseline [22% (hypothermia) and 21% (normothermia)]. One-year survival did not differ significantly between hypothermia and normothermia groups (44% [138/317] and 38% [113/ 297], respectively; relative risk, 1.15; 95% CI, 0.95 to 1.38; p = 0.15). Incidences of blood-product use, infection, and serious cardiac arrhythmia adverse events, and 28-day mortality, did not differ between groups.
CONCLUSIONS: Analysis of combined data from two paediatric cardiac arrest targeted temperature management trials including both in-hospital and out-of-hospital cases revealed that hypothermia, as compared with normothermia, did not confer a significant benefit in survival with favourable functional outcome at one year.
参考来源
- Scholefield BR, Silverstein FS, Telford R, et al. Therapeutic hypothermia after paediatric cardiac arrest: Pooled randomized controlled trials. Resuscitation. 2018. PMID: 30291883. doi:10.1016/j.resuscitation.2018.09.011
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。